

# Prostatic Diseases and Male Voiding Dysfunction

## Urodynamic Effects of Volume-adjustable Balloons for Treatment of Postprostatectomy Urinary Incontinence

Elaine Utomo, Jan Groen, Irene H. Vroom, Ron van Mastrigt, and Bertil F. M. Blok

<b>OBJECTIVE</b>	To evaluate the urodynamic changes in patients treated with Adjustable Continence Therapy for men (ProACT) for postprostatectomy incontinence and to explore the clinical and urodynamic preimplantation parameters as predictors of clinical outcome.
<b>MATERIALS AND METHODS</b>	Patients underwent urodynamic studies before and after ProACT implantation. ProACT was considered successful if patients used none or 1 dry precautionary pad and unsuccessful if the patient reported $\geq 1$ wet pad/d. The pre- and postimplantation assessments were retrospectively compared within and between the success and nonsuccess groups. Multivariate logistic regression analysis was performed to investigate the association between the preimplantation variables and the clinical outcomes of ProACT implantation.
<b>RESULTS</b>	A total of 49 patients were included, 37 with successful and 12 with unsuccessful clinical outcome. Postimplantation urodynamic studies were performed a median of 9 months after ProACT implantation. In the successfully treated patients, maximum free flow rate, bladder contractility index, maximum of bladder contractility parameter W, and bladder voiding efficiency were significantly lower after implantation. The detrusor pressure at maximum flow rate, postvoid residual urine volume, and bladder outlet obstruction index were significantly higher. A longer duration of urinary incontinence, the use of $>5$ pads daily, and a smaller cystometric bladder capacity were all independently associated with unsuccessful clinical outcome after ProACT implantation.
<b>CONCLUSION</b>	ProACT implantation with successful clinical outcome resulted in greater urethral resistance during voiding and reduced bladder contraction strength. A longer duration of incontinence, the use of $>5$ pads daily, and a smaller cystometric bladder capacity were independent predictors of unsuccessful clinical outcomes, suggesting ProACT implantation should be considered sooner, rather than later, after conservative treatment of postprostatectomy incontinence has failed. UROLOGY 81: 1308–1314, 2013. © 2013 Elsevier Inc.

Men who have undergone radical prostatectomy (RP) for prostate cancer are at risk of stress urinary incontinence (SUI). The prevalence of postprostatectomy incontinence (PPI) has ranged from 2% to nearly 60%.<sup>1</sup> PPI is a distressing disorder that affects men's quality of life<sup>2</sup> and often requires treatment. Surgical techniques can be considered if conservative treatment fails. Implantation of an artificial urinary sphincter (AUS) has been the reference standard surgical treatment of PPI; however, recently, less-invasive and less-expensive techniques have been introduced as potential alternatives.<sup>3</sup>

The Adjustable Continence Therapy system for men (ProACT, Uromedica, Minneapolis, MN) is a minimally invasive implant, consisting of 2 volume-adjustable balloons.<sup>4</sup> These balloons are placed paraurethraly just beneath the bladder neck. Each balloon is attached by a conduit to a port placed subcutaneously in the scrotum, allowing for separate volume adjustments after the initial implantation using an isotonic solution of contrast medium. The balloon volume is adjusted to create bilateral urethral compression. The balloons are adjusted until continence is achieved and the optimal balance between bladder emptying and continence has been obtained.

The clinical results of ProACT reported during the past few years have shown dry or improved rates ranging from 56% to 92%.<sup>5-7</sup> Nevertheless, the urodynamic working mechanism of ProACT implantation is not fully understood and needs additional elucidation. For

**Financial Disclosure:** The authors declare that they have no relevant financial interests.

From the Department of Urology, Erasmus Medical Center, Rotterdam, the Netherlands

Reprint requests: Elaine Utomo, M.D., Department of Urology, Erasmus Medical Center, Room Na-1710, P.O. Box 2040, 3000 CA Rotterdam, the Netherlands.

E-mail: e.utomo@erasmusmc.nl

Submitted: October 29, 2012, accepted (with revisions): January 14, 2013

instance, it is unknown whether the bilateral compression causes greater urethral resistance, and whether this resistance affects bladder contractility.

Various studies have shown acceptable to good reproducibility in diagnosing bladder outlet obstruction using urodynamic studies (UDS), varying from same session testing<sup>8-10</sup> to repeated testing within 6 months.<sup>8,10</sup>

We, therefore, performed a study to evaluate the urodynamic changes in patients treated with ProACT for PPI and to explore which clinical and urodynamic preimplantation parameters are associated with the non-successful clinical outcome of ProACT implantation.

## MATERIAL AND METHODS

Since May 2007, ProACT balloons have been used at our department for the treatment of male SUI. The ProACT implantation procedure has been previously described.<sup>4</sup> In brief, using fluoroscopic guidance, 2 balloons were placed immediately adjacent to the urethra at the level of the bladder neck by way of 2 small incisions in the perineum. Each balloon was then filled with 1 mL of isotonic contrast medium solution. All implantation procedures were performed by the same surgeon. The patients were assessed after implantation at regular 3-4-week intervals. If required, we adjusted the balloon volume with a maximum of 1 mL in each balloon per visit by way of the subcutaneous port sited in the scrotum.

The local ethical committee approved the retrospective analysis of the data from all patients who had undergone ProACT implantation for PPI. All patients who had undergone ProACT implantation for PPI in our clinic until June 2012 with UDS available before and after ProACT implantation, were eligible for inclusion in the present analysis. The exclusion criteria for ProACT implantation included external radiotherapy for positive margins, salvage radiotherapy for increased prostate-specific antigen levels after RP,<sup>4,11</sup> and bladder neck sclerosis or urethral stenosis. The data collected from the patient medical charts included date of birth, date of RP, previous treatment of SUI, the use of anticholinergics, the reported number of incontinence pads used daily (PPD) before ProACT implantation, the date of ProACT implantation, the number of ProACT balloon adjustments and total ProACT balloon volume after implantation; the reported use of PPD after ProACT balloon adjustments, and a nonvalidated Dutch translation of the bother question<sup>12</sup> of the International Prostate Symptom Score<sup>13</sup> (IPSS-BQ). The IPSS-BQ is a single disease-specific quality-of-life question that assesses the degree to which patients find their symptoms bothersome. The score of the IPSS-BQ ranges from 0 to 6, with a greater score indicating more bother from the patient's urinary condition. Patients were defined as having "mild" urinary incontinence if the PPD usage was 1 or 2, "moderate" if it was >2-5, and "severe" if >5 or if a condom catheter was needed.

After the volume adjustments, ProACT implantation was either "successful" or "unsuccessful." We defined "successful" if the patient was subjectively dry (ie, if he used 0 PPD or 1 precautionary PPD). This precautionary pad is the smallest male incontinence pad available. "Unsuccessful" was defined as patients reporting the use of  $\geq 1$  wet PPD. Patients were excluded if a surgical intervention, other than ProACT implantation, had occurred between the preimplantation and

postimplantation UDS, such as internal urethrotomy, an AUS was in situ, or if the patient had a neurologic disease that could affect voiding function.

Before implantation of the ProACT balloons, the UDS was performed to determine the bladder and sphincter function. This was repeated after the balloon volume adjustments were completed. The latter, postimplantation, UDS was a part of the standard evaluation protocol in our clinic either to detect bladder outlet obstruction in successful patients or to evaluate the persistence of incontinence in unsuccessful patients (eg, urge incontinence).

Each UDS was performed according to the International Continence Society standards<sup>14</sup> and included free uroflowmetry, 2 filling cystometries, and subsequent pressure-flow studies (PFS). The maximum flow rate (Q<sub>max</sub>) and average flow rate were measured using a rotating disk flow meter. A 7F double-lumen transurethral catheter was used for cystometry and PFS and were left in situ during voiding. The bladder was filled to the maximum cystometric capacity at a medium rate (50 mL/min) using filling fluid at room temperature.<sup>14</sup> When filling the bladder was not possible because of total incontinence, the patient was asked to manually squeeze the urethra. The intravesical pressure transducers were placed at the level of the superior edge of the pubic symphysis. The pressure was zeroed to the atmospheric pressure.

The outcome variables derived from the cystometric studies were the parameters characterizing detrusor overactivity (DO) and compliance. DO was defined as the occurrence of involuntary detrusor contractions during the filling phase of the bladder, without a lower limit for the amplitude of an involuntary detrusor contraction.<sup>15</sup> Compliance was calculated at cystometric capacity<sup>15</sup> or at 500 mL if the capacity was >500 mL. The outcome variables derived from the PFS were Q<sub>max</sub>, detrusor pressure at Q<sub>max</sub> (P<sub>det</sub>Q<sub>max</sub>), and parameters of urethral resistance and bladder contraction strength. The parameter for urethral resistance was the bladder outlet obstruction index (BOOI = P<sub>det</sub>Q<sub>max</sub> - 2 × Q<sub>max</sub>).<sup>16</sup> The parameters for bladder contraction strength were the bladder contractility index (BCI = P<sub>det</sub>Q<sub>max</sub> + 5 × Q<sub>max</sub>),<sup>16</sup> and parameter W,<sup>17</sup> an approximation of the power generated by the detrusor muscle per unit of bladder wall area. The maximum of W (W<sub>max</sub>) and the value of W at Q<sub>max</sub> (W/Q<sub>max</sub>) were used as contractility parameters.<sup>17,18</sup> Additionally, we determined the voided volume, postvoid residual urine (PVR) volume, cystometric bladder capacity (sum of the voided and PVR volume during PFS), and bladder voiding efficiency ([voided volume/bladder capacity] × 100).<sup>16</sup> In the case of repeated PVR measurements, we used the lowest value measured.

The measurement with the largest cystometric capacity was used to assess the filling phase. The PFS with the greatest Q<sub>max</sub> was used to assess the voiding phase. Artifacts were corrected manually. The urodynamic data were analyzed using AUDACT software, version 4.50 (Andromeda Medizinische Systeme GmbH, Taufkirchen, Germany).

Statistical analysis was performed using SPSS Statistics, release 20.0.0.1 (IBM, Armonk, NY). Statistical significance was defined as  $P < .05$ . The median and interquartile range (lower quartile to upper quartile) are reported for continuous data. For discrete data, counts and percentages are reported.

To assess the change in outcome before and after ProACT implantation within the success and nonsuccess group, the Wilcoxon signed rank test was used for continuous variables and McNemar's test for categorical variables. The Mann-Whitney U

test was used to compare the preimplantation urodynamic parameters between the success and nonsuccess groups for continuous variables and the chi-square test for categorical variables.

Multivariate logistic regression analysis was conducted using the backward likelihood ratio method. All preimplantation patient characteristics and preimplantation urodynamic parameters with  $P < .05$  on univariate analysis were considered in building the model to investigate the association between these variables and a nonsuccessful outcome.

## RESULTS

From May 2007 to June 2012, 81 patients with PPI received implantation of the ProACT balloons (Fig. E1). At the last follow-up visit, 8 patients were still in the process of postimplantation balloon adjustments and had not yet undergone the postimplantation UDS. Another 8 patients had their ProACT devices removed because of infection ( $n = 2$ ), dislocation of the device ( $n = 3$ ), or tissue erosion ( $n = 3$ ). A final 8 patients met an exclusion criterion: 2 had undergone surgical intervention between the preimplantation and postimplantation UDS, 3 had an AUS in situ, and 3 developed a neurologic disease (2 experienced a stroke and 1 developed Alzheimer's disease). Thus, 49 of the 57 patients (86%) completed the postimplantation UDS and were included in our study.

ProACT was the first surgical SUI therapy after failed pelvic floor muscle training in 38 of the 49 patients (78%). Of the 49 patients, 15 (31%) had mild, 18 (37%) had moderate, and 16 (33%) had severe SUI.

After implantation, none of the 49 included patients had symptoms of persistent urinary retention or symptomatic urinary tract infection. ProACT implantation was successful in 37 patients and not successful in 12, although 4 of these 12 patients had a reduction in PPD of  $\geq 50\%$ . These 12 unsuccessfully treated patients had either received the maximal allowed filling volume ( $n = 8$ ) or had noted absolutely no improvement after several adjustments ( $n = 4$ ). The success rate was 93% (14 of 15) in patients with mild incontinence, 83% (15 of 18) in those with moderate incontinence, and 50% (8 of 16) in those with severe incontinence.

The patient characteristics were compared between the success and nonsuccess groups (Table 1). In the nonsuccess group, the median age was 7.5 years older ( $P = .001$ ), the median duration of urinary incontinence was 7.5 years longer ( $P = .001$ ), and the incontinence was more severe ( $P = .01$ ). As expected, the patients in the nonsuccess group had a greater balloon volume ( $P < .001$ ) and a greater IPSS-BQ score ( $P < .001$ ) than did the patients in the success group.

The urodynamic outcomes before and after implantation for the successful and unsuccessful groups are listed in Table 2. The preimplantation cystometric bladder capacity and free flow  $Q_{max}$  were significantly lower in the nonsuccess group than in the success group (Table 2). The other parameters, including BCI

( $P = .06$ ), were not significantly different between the 2 groups.

In the nonsuccess group, only the average flow rate was significantly lower after implantation. We did not find any other significant differences between the urodynamic parameters before and after ProACT implantation. In the success group, 8 patients (22%) had DO during the preimplantation UDS, of whom 3 continued to have DO during the postimplantation UDS. Also, 7 patients showed de novo DO with threshold volumes of  $\geq 250$  mL. No statistically significant differences were found before and after implantation in the proportion of patients with DO, the cystometric bladder capacity, or bladder compliance ( $P = .77$ ,  $P = .31$ , and  $P = .79$ , respectively). The urethral resistance during voiding, as described by BOOI, was significantly greater after implantation ( $P < .001$ ). The BOOI increased in most patients after implantation (Fig. 1). In 3 patients, the BOOI was lower after ProACT implantation. Four patients had a postimplantation BOOI  $> 40$  but had no clinical symptoms of symptomatic urinary retention or persistent urinary tract infection. The maximum free flow rate and average flow rate were significantly lower after implantation, and the PVR volume was significantly greater, with a median of 0 mL (interquartile range 0-25). Five patients (14%) had a PVR volume  $> 100$  mL. Consequently, the bladder voiding efficiency was significantly lower after implantation ( $P < .001$ ). The proportion of patients who had to strain during the PFS (35%) was not significantly increased after implantation (32%). The bladder contraction strength, characterized by the BCI and  $W_{max}$ , was significantly lower after implantation ( $P < .001$  and  $P = .004$ , respectively); however,  $W_{Qmax}$  was not ( $P = .09$ ).

Multivariate logistic regression analysis was performed to explore both the clinical and the urodynamic preimplantation parameters as predictors of outcome. A longer duration of urinary incontinence ( $P = .007$ ), severe incontinence ( $P = .02$ ), and smaller cystometric bladder capacity ( $P = .05$ ) were all independently associated with a nonsuccessful outcome of ProACT implantation (Table 3). Patient age and free flow  $Q_{max}$  were not independently associated with the clinical outcome.

## COMMENT

The present study was designed to describe the urodynamic changes after implantation of ProACT for PPI. Our results have shown that successful treatment with ProACT increased urethral resistance and could affect the parameters of bladder contraction strength. In the successfully treated patients, a clear shift could be seen from the unobstructed area toward the equivocal and—to a lesser extent—to the obstructed area of the provisional International Continence Society nomogram (Fig. 1). Nevertheless, no signs of clinical obstruction were found, because the proportion of patients who had to strain during voiding did not differ after ProACT implantation, and none of our patients had persistent urinary retention

**Table 1.** Patient characteristics

Characteristic	Success (n = 37)	Nonsuccess (n = 12)	P Value*
Before implantation			
Age (y)			.001
Median	68.0	75.5	
IQR	63.5-72.5	69.5-79.8	
Previous treatment of SUI			.22
Only PFMT	29 (78)	9 (75)	
Bulking agent	0 (0)	1 (8)	
AUS	2 (5)	1 (8)	
Unknown	6 (16)	1 (8)	
Urinary incontinence duration (y)			.001
Median	3.0	10.5	
IQR	1.0-6.0	6.0-13.5	
Incontinence severity			.01
Mild (1 or 2 PPD)	14 (38)	1 (8)	
Moderate (>2-5 PPD)	15 (41)	3 (25)	
Severe (>5 PPD)	8 (22)	8 (67)	
After implantation and balloon adjustments			
Interval between ProACT and UDS (mo)			<.001
Median	7.0	13.5	
IQR	5.0-9.0	10.3-22.0	
Interval between last balloon adjustment and UDS (mo)			.87
Median	3.0	2.5	
IQR	2.0-3.0	1.0-4.0	
Balloon volume (mL)			<.001
Median	4.0	7.5	
IQR	2.9-6.0	6.5-8.9	
Adjustments (n)			.002
Median	3.0	6.0	
IQR	2.0-5.5	5.0-7.0	
Incontinence severity			NA
None (0 or 1 security PPD)	37 (100)	0	
Mild (1 or 2 PPD)	0	4 (33)	
Moderate (>2-5 PPD)	0	2 (17)	
Severe (>5 PPD)	0	6 (50)	
IPSS-BQ <sup>†</sup>			<.001
Delighted	13 (35)	0 (0)	
Pleased	13 (35)	0 (0)	
Mostly satisfied	5 (14)	1 (8)	
Mixed	2 (5)	5 (42)	
Mostly dissatisfied	1 (3)	1 (8)	
Unhappy	1 (3)	4 (33)	
Terrible	1 (3)	1 (8)	
Missing	1 (3)	0 (0)	

AUS, artificial urinary sphincter; IPSS-BQ, International Prostate Symptom Score bother question; IQR, interquartile range (lower quartile to upper quartile); NA, not applicable; PFMT, pelvic floor muscle training; PPD, incontinence pads used per day; RP, radical prostatectomy; UDS, urodynamic studies.

Data in parentheses are percentages.

\* Mann-Whitney *U* test used for continuous variables and chi-square test for categorical variables.

<sup>†</sup> "If you were to spend the rest of your life with your urinary condition just the way it is now, how would you feel about that?"

or symptomatic urinary tract infections during our follow-up period. Also, treatment success was demonstrated by patient-reported PPD use and IPSS-BQ, both important for quality of life. In 3 patients, the BOOI was lower after implantation, although the absolute differences were small and did not result in a clear change in the BOOI category assignments (Fig. 1).

The BCI and Wmax, representing bladder contractility, were significantly lower after ProACT implantation with a successful outcome. Several explanations are possible for this unexpected observation. First, the bladder can use its muscle contractility to generate a high

pressure at low flow rate or a high flow rate at a low pressure.<sup>19</sup> Therefore, a contractility parameter should combine these 2 properties in an equation, such that when the muscle contractility does not change but the balance between the pressure and flow rate changes from external causes (eg, a change in urethral resistance), the contractility parameter would remain constant. It might be that in the equations that define Wmax and BCI, the decrease in Qmax caused by the balloon volume is not adequately compensated by the accompanying increase in PdetQmax. This would result in a decrease in contractility parameter value, which would not represent a true

**Table 2.** Urodynamic data before and after ProACT implantation

Parameter	Success Group (n = 37)			Nonsuccess Group (n = 12)			P Value <sup>†</sup>
	Before Implantation	After Implantation	P Value*	Before Implantation	After Implantation	P Value*	
<b>Storage</b>							
Cystometric bladder capacity (mL)			.31			.27	.003
Median	514.0	504.0		384.5	367.5		
IQR	416.5-574.0	396.5-607.0		257.0-425.5	278.8-528.8		
Compliance (mL/cm H <sub>2</sub> O)			.79			.16	.33
Median	34.9	44.3		26.5	17.1		
IQR	18.6-94.0	22.1-70.8		16.4-46.4	12.3-24.7		
DO (n)	8 (22)	10 (27)	.77	5 (42)	7 (58)	.50	.17
<b>Voiding</b>							
Straining (n)	13 (35)	12 (32)	.13	5 (42)	7 (58)	.22	.91
Free flow Qmax (mL/s)			<.001			.07	.01
Median	18.2	9.9		9.6	5.5		
IQR	11.7-24.9	6.9-14.1		6.0-19.7	3.3-8.4		
Qave (mL/s)			<.001			.03	.12
Median	10.5	5.1		5.7	2.9		
IQR	6.2-13.7	3.2-6.8		3.7-12.1	1.7-4.9		
PdetQmax (cm H <sub>2</sub> O)			<.001			.33	.85
Median	25.9	38.6		25.3	34.3		
IQR	19.1-31.5	31.4-46.2		13.8-42.9	11.4-44.4 <sup>‡</sup>		
PVR (mL)			.005			.18	.56
Median	0	0		0	0		
IQR	0-0 <sup>‡</sup>	0-25		0-0	0-0		
<b>Urethral resistance</b>							
B00I			<.001			.16	.19
Median	-7.4	23.1		-0.9	16.2		
IQR	-22.3-4.2	6.0-34.3		-12.8-27.6	-23.7-34.5 <sup>‡</sup>		
<b>Bladder contraction strength</b>							
BCI			<.001			.96	.06
Median	107.3	81.2		85.5	72.7		
IQR	81.9-135.8	68.3-102.8		63.5-104.1	68.3-100.4 <sup>‡</sup>		
Wmax (W/m <sup>2</sup> )			.004			.53	.30
Median	9.9	7.1		8.4	8.3		
IQR	7.1-14.9	6.0-11.1		7.2-10.2	5.9-11.0 <sup>‡</sup>		
WQmax (W/m <sup>2</sup> )			.09			.72	.74
Median	6.2	6.0		7.0	5.1		
IQR	5.0-8.9	5.0-6.9		3.4-7.9	3.7-7.1 <sup>‡</sup>		
<b>Bladder emptying function</b>							
BVE (%)			<.001			.29	.14
Median	100.0	80.0		97.3	95.4		
IQR	94.7-100.0	56.6-100.0		93.3-99.9	88.8-100.0		

BCI, bladder contractility index; B00I, bladder outlet obstruction index; BVE, bladder voiding efficiency; DO, detrusor overactivity; PVR, postvoid residual (urine volume); PdetQmax, detrusor pressure at maximum flow rate; Qave, average flow rate; Qmax, maximum flow rate; Wmax, maximum of bladder contraction strength parameter W; WQmax, bladder contraction strength parameter W at Qmax; other abbreviations as in Table 1.

Data in parentheses are percentages.


\* Wilcoxon signed rank test used for continuous variables and McNemar's test for categorical variables to assess changes in outcomes before and after ProACT implantation.

† Statistical significances of preimplantation variables between success and nonsuccess groups explored using Mann-Whitney U test for continuous variables and chi-square test for categorical variables.

‡ Missing data for 1 patient.

decrease in muscle contractility. Second, in patients with urethral obstruction from benign prostatic hyperplasia, the bladder contractions might slowly decline prematurely, leaving a PVR volume.<sup>20</sup> This decline could cause a lower Wmax. It is likely that the decline does not affect the value of W at Qmax because the value of W at Qmax is usually attained earlier during the course of micturition than is Wmax. This was also observed in our group. Parameter WQmax was not significantly lower after ProACT implantation. Third, it is physiologically plausible that our finding of lower bladder contraction

strength could be caused by the decreased Qmax owing to the urethrovesical reflex. This reflex is responsible for the maintenance of the detrusor contraction in the normal bladder.<sup>21</sup> The reduced urine flow after ProACT implantation could thus lead to reduced stimulation of the bladder and, consequently, to a decreased bladder contraction strength. For these reasons, the lower bladder contraction strength we found could have resulted from an inadequacy of the equation used to estimate the bladder contractility in urinary incontinence or might have a physiologic explanation.



**Figure 1.** Graph showing detrusor pressure at maximum flow rate (PdetQmax) and maximum flow rate (Qmax) before (open circles) and after (black circles) implantation of Adjustable Continence Therapy for men (ProACT). Bold lines and arrows indicate that bladder outlet obstruction index was lower after ProACT implantation.

Our second objective was to explore the clinical and urodynamic preimplantation parameters as predictors of a nonsuccessful outcome after ProACT implantation. A longer duration of urinary incontinence and severe incontinence (>5 PPD) were independent clinical predictors of a nonsuccessful outcome. Possibly, scarred tissue around the neobladder neck from RP becomes less distensible as it ages. Consequently, inflation of the balloons might not result in sufficient urethral compression. Possibly, ProACT treatment should be considered sooner, rather than later, after conservative treatment of PPI has failed. Patients with severe incontinence were more likely to have an unsuccessful outcome after ProACT implantation than were patients with either mild or moderate incontinence. Still, 50% of patients with severe PPI achieved continence with ProACT implantation. ProACT implantation has been suggested as a part of a “step-up” approach<sup>22</sup> before opting for AUS, which can be considered in the case of more severe incontinence. Of the urodynamic parameters, only a smaller preimplantation cystometric bladder capacity was independently associated with nonsuccess. This finding is in line with the results from Warner et al<sup>23</sup> on the urodynamic effects of transobturator male slings in the treatment of SUI. They also found that a small bladder capacity might be a predictor of an unsuccessful outcome.<sup>23</sup>

DO is a urodynamic diagnosis and is not necessarily symptomatic or clinically relevant. Therefore, only patients who experienced urgency in everyday life were treated with anticholinergic agents. Of the 3 patients who continued to have DO after implantation, 2 were treated with anticholinergic agents, the third patient had a threshold volume of 500 mL and no urge symptoms in daily life. Of the 7 patients had de novo DO, only 1 required treatment with anticholinergic agents; the remaining 6 patients were asymptomatic and did not need treatment. The “de novo” DO might have been already

**Table 3.** Results of multivariate analysis for non-successful outcome

	OR	95% CI	P Value
Duration of incontinence (each year)	1.83	1.17-2.83	.007
Incontinence severity			Reference
Mild (1 or 2 PPD)			
Moderate (>2-5 PPD)	1.55	0.06-39.41	.79
Severe (>5 PPD)	136.42	2.10-9075.82	.02
Cystometric bladder capacity (each 10 mL)	0.91	0.82-1.0	.05

CI, confidence interval; OR, odds ratio; other abbreviations as in Table 1.

Candidates for inclusion in model included age, urinary incontinence duration, incontinence severity, maximum free flow rate, and cystometric bladder capacity.

present but missed by the UDS before ProACT implantation.<sup>24,25</sup>

Various studies on the operative and clinical results of ProACT implantation have been published.<sup>4,5,22,26,27</sup> These studies were all cohort and/or feasibility studies, and our study focused on the urodynamic outcomes. Although some studies have evaluated leak point pressures and uroflowmetry,<sup>5,26</sup> important urodynamic outcomes of ProACT implantation such as urethral resistance and bladder contraction strength have never before been evaluated after implantation.

The limitations of our study included the use of a non-validated IPSS-BQ and the lack of a cough stress test as outcome measures. Although other ProACT studies used the same classification for incontinence severity,<sup>27-30</sup> it might be somewhat arbitrary, because it can vary by merely volume intake. The relatively short follow-up and small number of patients were other limitations of our study. Still, to our knowledge, ours is the first study to review the urodynamic changes after ProACT implantation. Our results have provided a clear impression of the increased urethral resistance due to the paraurethral placed balloons to achieve continence. Studies with longer follow-up are needed to determine the effects of chronically increased urethral resistance on bladder function from ProACT implantation. For now, individual follow-up is important to achieve the right balance between patient satisfaction and urethral resistance.

## CONCLUSION

Our data have suggested that urethral resistance is increased to achieve continence with ProACT implantation without symptoms of clinical bladder outlet obstruction. We also found a decreased bladder contraction strength after continence was achieved with ProACT, which could be either an artifact or part of a physiologic phenomenon.

A longer incontinence duration, severe incontinence (defined by the use of >5 PPD), and a smaller cystometric bladder capacity were important predictors of a non-successful clinical outcome in patients undergoing

ProACT implantation. Therefore, ProACT treatment should be considered sooner, rather than later, after conservative treatment of PPI has failed.

**Acknowledgment.** To Dr. Mark F. Wildhagen for his statistical assistance and Dr. Adriaan J. van der Meer for his thorough reading of our report and providing very constructive comments, with sincere thanks.

## References

1. Buckley BS, Lapitan MC. Prevalence of urinary incontinence in men, women, and children—current evidence: findings of the Fourth International Consultation on Incontinence. *Urology*. 2010;76:265-270.
2. Kao TC, Cruess DF, Garner D, et al. Multicenter patient self-reporting questionnaire on impotence, incontinence and stricture after radical prostatectomy. *J Urol*. 2000;163:858-864.
3. Bauer RM, Bastian PJ, Gozzi C, et al. Postprostatectomy incontinence: all about diagnosis and management. *Eur Urol*. 2009;55:322-333.
4. Hubner WA, Schlarp OM. Treatment of incontinence after prostatectomy using a new minimally invasive device: adjustable continence therapy. *BJU Int*. 2005;96:587-594.
5. Gilling PJ, Bell DF, Wilson LC, et al. An adjustable continence therapy device for treating incontinence after prostatectomy: a minimum 2-year follow-up. *BJU Int*. 2008;102:1426-1430 [discussion 1430-1431].
6. Hubner WA, Schlarp OM. Adjustable continence therapy (ProACT): evolution of the surgical technique and comparison of the original 50 patients with the most recent 50 patients at a single centre. *Eur Urol*. 2007;52:680-686.
7. Kjaer L, Fode M, Norgaard N, et al. Adjustable continence balloons: clinical results of a new minimally invasive treatment for male urinary incontinence. *Scand J Urol Nephrol*. 2012;46:196-200.
8. Hansen F, Olsen L, Atan A, et al. Pressure-flow studies: short-time repeatability. *Neurourol Urodyn*. 1999;18:205-214.
9. Rosier PF, de la Rosette JJ, Koldewijn EL, et al. Variability of pressure-flow analysis parameters in repeated cystometry in patients with benign prostatic hyperplasia. *J Urol*. 1995;153:1520-1525.
10. Hashim H, Elhilali M, Bjerklund Johansen TE, et al. The immediate and 6-mo reproducibility of pressure-flow studies in men with benign prostatic enlargement. *Eur Urol*. 2007;52:1186-1193.
11. Kocjancic E, Crivellaro S, Ranzoni S, et al. Adjustable continence therapy for the treatment of male stress urinary incontinence: a single-centre study. *Scand J Urol Nephrol*. 2007;41:324-328.
12. O'Leary MP. Validity of the "bother score" in the evaluation and treatment of symptomatic benign prostatic hyperplasia. *Rev Urol*. 2005;7:1-10.
13. Barry MJ, Fowler FJ Jr, O'Leary MP, et al. The American Urological Association symptom index for benign prostatic hyperplasia: the Measurement Committee of the American Urological Association. *J Urol*. 1992;148:1549-1557 [discussion 1564].
14. Schafer W, Abrams P, Liao L, et al. Good urodynamic practices: uroflowmetry, filling cystometry, and pressure-flow studies. *Neurourol Urodyn*. 2002;21:261-274.
15. Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. *Urology*. 2003;61:37-49.
16. Abrams P. Bladder outlet obstruction index, bladder contractility index and bladder voiding efficiency: three simple indices to define bladder voiding function. *BJU Int*. 1999;84:14-15.
17. Griffiths D, van Mastrigt R, Bosch R. Quantification of urethral resistance and bladder function during voiding, with special reference to the effects of prostate size reduction on urethral obstruction due to benign prostatic hyperplasia. *Neurourol Urodyn*. 1989;8:17-27.
18. Griffiths DJ, Constantinou CE, van Mastrigt R. Urinary bladder function and its control in healthy females. *Am J Physiol*. 1986;251:R225-R230.
19. Van Mastrigt R. Application of animal and physical models to human cystometry. In: Drife JO, Hilton PJ, Stanton SL, eds. *Micturition*. London: Springer; 1990:55-79.
20. Van Mastrigt R, Rollema HJ. The prognostic value of bladder contractility in transurethral resection of the prostate. *J Urol*. 1992;148:1856-1860.
21. Shafik A, Shafik IA, El Sibai O, et al. Effect of urethral stimulation on vesical contractile activity. *Am J Med Sci*. 2007;334:240-243.
22. Martens FM, Lampe MI, Heesakkers JP. ProACT for stress urinary incontinence after radical prostatectomy. *Urol Int*. 2009;82:394-398.
23. Warner JN, Grimsby GM, Tyson MD, et al. Bladder capacity on preoperative urodynamics may impact outcomes on transobturator male slings. *Neurourol Urodyn*. 2012;31:1124-1127.
24. Broekhuis SR, Kluivers KB, Hendriks JC, et al. Reproducibility of same session repeated cystometry and pressure-flow studies in women with symptoms of urinary incontinence. *Neurourol Urodyn*. 2010;29:428-431.
25. Digesu GA, Khullar V, Cardozo L, et al. Overactive bladder symptoms: do we need urodynamics? *Neurourol Urodyn*. 2003;22:105-108.
26. Trigo-Rocha F, Gomes CM, Pompeo AC, et al. Prospective study evaluating efficacy and safety of adjustable continence therapy (ProACT) for post radical prostatectomy urinary incontinence. *Urology*. 2006;67:965-969.
27. Roupret M, Misrai V, Gosseine PN, et al. Management of stress urinary incontinence following prostate surgery with minimally invasive adjustable continence balloon implants: functional results from a single center prospective study. *J Urol*. 2011;186:198-203.
28. Gregori A, Simonato A, Lissiani A, et al. Transrectal ultrasound guided implantation of the ProACT adjustable continence therapy system in patients with post-radical prostatectomy stress urinary incontinence: a pilot study. *J Urol*. 2006;176:2109-2113 [discussion 2113].
29. Crivellaro S, Tosco L, Palazzetti A, et al. Geometrical stepper-guided navigation system for ProACT implant under transrectal ultrasound control: preliminary data. *Urol Int*. 2012;89:473-479.
30. Gregori A, Romano AL, Scieri F, et al. Transrectal ultrasound-guided implantation of adjustable continence therapy (ProACT): surgical technique and clinical results after a mean follow-up of 2 years. *Eur Urol*. 2010;57:430-436.

## APPENDIX

### SUPPLEMENTARY DATA

Supplementary material related to this article can be found at <http://dx.doi.org/10.1016/j.urology.2013.01.020>.